APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sexually Transmitted Diseases (STDs) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sexually Transmitted Diseases (STDs) Drug Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchSexually Transmitted Diseases (STDs) Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sexually Transmitted Diseases (STDs) Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Sexually Transmitted Diseases (STDs) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sexually Transmitted Diseases (STDs) Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Sexually Transmitted Diseases (STDs) Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Sexually Transmitted Diseases (STDs) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sexually Transmitted Diseases (STDs) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sexually Transmitted Diseases (STDs) Drug market include Bayer Healthcare, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, Hoffmann La Roche, AbbVie, Inc., Pfizer, Eli Lilly and Merck & Co., Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Sexually Transmitted Diseases (STDs) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sexually Transmitted Diseases (STDs) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sexually Transmitted Diseases (STDs) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sexually Transmitted Diseases (STDs) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Sexually Transmitted Diseases (STDs) Drug Segment by Company

Bayer Healthcare

Bristol-Myers Squibb

Gilead Sciences

GlaxoSmithKline Plc

Hoffmann La Roche

AbbVie, Inc.

Pfizer

Eli Lilly

Merck & Co., Inc.

Johnson & Johnson

Sexually Transmitted Diseases (STDs) Drug Segment by Type

Chlamydia

Genital herpes

HPV

Syphilis

Gonorrhea

HIV / AIDS

Sexually Transmitted Diseases (STDs) Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Sexually Transmitted Diseases (STDs) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sexually Transmitted Diseases (STDs) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Sexually Transmitted Diseases (STDs) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sexually Transmitted Diseases (STDs) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Sexually Transmitted Diseases (STDs) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sexually Transmitted Diseases (STDs) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sexually Transmitted Diseases (STDs) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sexually Transmitted Diseases (STDs) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sexually Transmitted Diseases (STDs) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sexually Transmitted Diseases (STDs) Drug industry.

Chapter 3: Detailed analysis of Sexually Transmitted Diseases (STDs) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Sexually Transmitted Diseases (STDs) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Sexually Transmitted Diseases (STDs) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sexually Transmitted Diseases (STDs) Drug Industry Trends Table 2. Sexually Transmitted Diseases (STDs) Drug Industry Drivers Table 3. Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges Table 4. Sexually Transmitted Diseases (STDs) Drug Industry Restraints Table 5. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sexually Transmitted Diseases (STDs) Drug Revenue Share by Company (2021-2026) Table 7. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Company (2021-2026) Table 9. Global Sexually Transmitted Diseases (STDs) Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Sexually Transmitted Diseases (STDs) Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Sexually Transmitted Diseases (STDs) Drug Key Company Manufacturing Base & Headquarters Table 12. Global Sexually Transmitted Diseases (STDs) Drug Company, Product Type & Application Table 13. Global Sexually Transmitted Diseases (STDs) Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Sexually Transmitted Diseases (STDs) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Chlamydia Table 18. Significant Companies of Genital herpes Table 19. Significant Companies of HPV Table 20. Significant Companies of Syphilis Table 21. Significant Companies of Gonorrhea Table 22. Significant Companies of HIV / AIDS Table 23. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Type (2021-2026) Table 27. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Type (2027-2032) Table 28. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type (2021-2026) Table 32. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Pharmacies Table 34. Significant Companies of Online Pharmacies Table 35. Significant Companies of Retail Pharmacies Table 36. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Application (2021-2026) Table 40. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Application (2027-2032) Table 41. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application (2021-2026) Table 45. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application (2027-2032) Table 46. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2021-2026) Table 49. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2027-2032) Table 51. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Region (2021-2026) Table 54. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Region (2027-2032) Table 56. Global Sexually Transmitted Diseases (STDs) Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Sexually Transmitted Diseases (STDs) Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Sexually Transmitted Diseases (STDs) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 61. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2021-2026) Table 62. Global Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2027-2032) Table 64. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Market Share by Country (2027-2032) Table 68. Bayer Healthcare Company Information Table 69. Bayer Healthcare Business Overview Table 70. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 72. Bayer Healthcare Recent Development Table 73. Bristol-Myers Squibb Company Information Table 74. Bristol-Myers Squibb Business Overview Table 75. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 77. Bristol-Myers Squibb Recent Development Table 78. Gilead Sciences Company Information Table 79. Gilead Sciences Business Overview Table 80. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 82. Gilead Sciences Recent Development Table 83. GlaxoSmithKline Plc Company Information Table 84. GlaxoSmithKline Plc Business Overview Table 85. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 87. GlaxoSmithKline Plc Recent Development Table 88. Hoffmann La Roche Company Information Table 89. Hoffmann La Roche Business Overview Table 90. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 92. Hoffmann La Roche Recent Development Table 93. AbbVie, Inc. Company Information Table 94. AbbVie, Inc. Business Overview Table 95. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 97. AbbVie, Inc. Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 102. Pfizer Recent Development Table 103. Eli Lilly Company Information Table 104. Eli Lilly Business Overview Table 105. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 107. Eli Lilly Recent Development Table 108. Merck & Co., Inc. Company Information Table 109. Merck & Co., Inc. Business Overview Table 110. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 112. Merck & Co., Inc. Recent Development Table 113. Johnson & Johnson Company Information Table 114. Johnson & Johnson Business Overview Table 115. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 117. Johnson & Johnson Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Sexually Transmitted Diseases (STDs) Drug Distributors List Table 121. Sexually Transmitted Diseases (STDs) Drug Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Sexually Transmitted Diseases (STDs) Drug Product Image Figure 2. Global Sexually Transmitted Diseases (STDs) Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Sexually Transmitted Diseases (STDs) Drug Sales (2021-2032) & (K Units) Figure 5. Global Sexually Transmitted Diseases (STDs) Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Sexually Transmitted Diseases (STDs) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Chlamydia Image Figure 10. Genital herpes Image Figure 11. HPV Image Figure 12. Syphilis Image Figure 13. Gonorrhea Image Figure 14. HIV / AIDS Image Figure 15. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type (2021-2032) Figure 21. Hospital Pharmacies Image Figure 22. Online Pharmacies Image Figure 23. Retail Pharmacies Image Figure 24. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application (2021-2032) Figure 30. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Sexually Transmitted Diseases (STDs) Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Sexually Transmitted Diseases (STDs) Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Chlamydia
  • Genital herpes
  • HPV
  • Syphilis
  • Gonorrhea
  • HIV / AIDS
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline Plc
  • Hoffmann La Roche
  • AbbVie, Inc.
  • Pfizer
  • Eli Lilly
  • Merck & Co., Inc.
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032)
  4. 1.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Sexually Transmitted Diseases (STDs) Drug Market Dynamics
  1. 2.1 Sexually Transmitted Diseases (STDs) Drug Industry Trends
  2. 2.2 Sexually Transmitted Diseases (STDs) Drug Industry Drivers
  3. 2.3 Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges
  4. 2.4 Sexually Transmitted Diseases (STDs) Drug Industry Restraints
3 Sexually Transmitted Diseases (STDs) Drug Market by Company
  1. 3.1 Global Sexually Transmitted Diseases (STDs) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Sexually Transmitted Diseases (STDs) Drug Average Price by Company (2021-2026)
  5. 3.5 Global Sexually Transmitted Diseases (STDs) Drug Company Ranking (2024-2026)
  6. 3.6 Global Sexually Transmitted Diseases (STDs) Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Sexually Transmitted Diseases (STDs) Drug Company Product Type and Application
  8. 3.8 Global Sexually Transmitted Diseases (STDs) Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Sexually Transmitted Diseases (STDs) Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Sexually Transmitted Diseases (STDs) Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Sexually Transmitted Diseases (STDs) Drug Market by Type
  1. 4.1 Sexually Transmitted Diseases (STDs) Drug Type Introduction
  2. 4.1.1 Chlamydia
  3. 4.1.2 Genital herpes
  4. 4.1.3 HPV
  5. 4.1.4 Syphilis
  6. 4.1.5 Gonorrhea
  7. 4.1.6 HIV / AIDS
  8. 4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type
  9. 4.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type
  13. 4.3.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type (2021-2032)
5 Sexually Transmitted Diseases (STDs) Drug Market by Application
  1. 5.1 Sexually Transmitted Diseases (STDs) Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application
  6. 5.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application
  10. 5.3.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application (2021-2032)
6 Sexually Transmitted Diseases (STDs) Drug Regional Sales and Value Analysis
  1. 6.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2027-2032)
  5. 6.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Sexually Transmitted Diseases (STDs) Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032)
  12. 6.6.2 North America Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032)
  21. 6.9.2 South America Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Sexually Transmitted Diseases (STDs) Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Country, 2025 VS 2032
7 Sexually Transmitted Diseases (STDs) Drug Country-level Sales and Value Analysis
  1. 7.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032)
  6. 7.4 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Sexually Transmitted Diseases (STDs) Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Sexually Transmitted Diseases (STDs) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer Healthcare
  2. 8.1.1 Bayer Healthcare Company Information
  3. 8.1.2 Bayer Healthcare Business Overview
  4. 8.1.3 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  6. 8.1.5 Bayer Healthcare Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 GlaxoSmithKline Plc
  20. 8.4.1 GlaxoSmithKline Plc Company Information
  21. 8.4.2 GlaxoSmithKline Plc Business Overview
  22. 8.4.3 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  24. 8.4.5 GlaxoSmithKline Plc Recent Developments
  25. 8.5 Hoffmann La Roche
  26. 8.5.1 Hoffmann La Roche Company Information
  27. 8.5.2 Hoffmann La Roche Business Overview
  28. 8.5.3 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  30. 8.5.5 Hoffmann La Roche Recent Developments
  31. 8.6 AbbVie, Inc.
  32. 8.6.1 AbbVie, Inc. Company Information
  33. 8.6.2 AbbVie, Inc. Business Overview
  34. 8.6.3 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  36. 8.6.5 AbbVie, Inc. Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Merck & Co., Inc.
  50. 8.9.1 Merck & Co., Inc. Company Information
  51. 8.9.2 Merck & Co., Inc. Business Overview
  52. 8.9.3 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  54. 8.9.5 Merck & Co., Inc. Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Sexually Transmitted Diseases (STDs) Drug Value Chain Analysis
  2. 9.1.1 Sexually Transmitted Diseases (STDs) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Sexually Transmitted Diseases (STDs) Drug Sales Mode & Process
  6. 9.2 Sexually Transmitted Diseases (STDs) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Sexually Transmitted Diseases (STDs) Drug Distributors
  9. 9.2.3 Sexually Transmitted Diseases (STDs) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst